Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Inyta

- PMLiVE

NICE set to reject wider use of Eisai’s Halaven

Issues draft guidance recommending against second-line use in breast cancer

- PMLiVE

MHRA joins Instagram as part of Yellow Card drive

UK medicines regulator follows in the footsteps of NICE in using the channel

- PMLiVE

Sutent gets FDA approval for early use in kidney cancer

Decision could help Pfizer combat competition from BMS' Opdivo and Yervoy

National Institute for Health and Care Excellence NICE logo

NICE backs two advanced breast cancer drugs after price cuts

An estimated 8,000 women will be eligible to receive the drugs due to discounts

- PMLiVE

Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

Women on Kisqali were found to have a longer PFS than those on hormonal therapy alone

Pharma’s digital patient engagement innovators identified

Novartis, Pfizer and Sanofi named best-in-class by Decision Resources Group

- PMLiVE

Exploring serious market access roadblocks for rare bleeding disorders

Ensuring that sufferers get the treatment they require

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

- PMLiVE

NICE backs Pfizer’s Xeljanz for RA

But UK’s cost-effectiveness watchdog removes two drugs from CDF

- PMLiVE

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Would follow in the footsteps of Novartis, Boehringer and Merck & Co if it does strike a deal

- PMLiVE

SMC backtracks on Janssen’s multiple myeloma treatment Darzalex

Will now recommend the first-in-class treatment after securing a discount

ABPI London offices

ABPI bid to overturn NICE’s budget impact rules fails

One in five new medicines would have been affected by the rejected policy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links